Blood feud: the man who blew the whistle on one of the deadliest prescription drugs ever

Book Cover
Average Rating
Publisher:
Varies, see individual formats and editions
Pub. Date:
Varies, see individual formats and editions
Language:
English
Description
Blood-boosting Procrit is Johnson & Johnson's biotech superstar. Behind its various brand names, it ranks as Medicare's most reimbursed drug. But Procrit performs frighteningly well, and can stimulate so many blood cells that thousands of patients die in unexplained and painful ways. And that's not all: Cancer patients, who often receive injections, are never warned that the drug stimulates tumor growth, too, prompting one leading hematologist to dub it "Miracle-Gro for cancer." While patients have no clue about the risks behind this poorly tested drug, Johnson & Johnson sales rep Mark Duxbury knows precisely what is happening-the pharma behemoth is blatantly marketing overdoses of the drug. Duxbury tries to warn his superiors and is forced to testify in a secret court about illegal schemes. But his honesty costs him his career. Humiliated and ignored for years, Duxbury is ultimately betrayed in a shockingly cruel way. The psychological trauma drives him to attempt suicide, yet he fights on for several more years until the heartbreaking end. A Civil Action's Jan Schlichtmann has taken on the case, and is back in federal district court in Massachusetts. And all the while, Johnson & Johnson has continued to push sales of Procrit. Blood Feud is award-winning journalist Kathleen Sharp's nail-biting expose of the Procrit case. Packed with corporate espionage, plot twists, and larger-than-life characters, it's as gripping as it is terrifyingly true.
Also in This Series
More Like This
More Copies In Prospector
Loading Prospector Copies...
More Details
ISBN:
9780525952404
9781452623764
Reviews from GoodReads
Loading GoodReads Reviews.
Tagging
Tags:

No Tags, Be the first to tag this record!


Staff View

Grouping Information

Grouped Work IDa9088616-1cea-8082-ea59-ccfab8c92029
Grouping Titleblood feud the man who blew the whistle on one of the deadliest prescription drugs ever
Grouping Authorsharp kathleen
Grouping Categorybook
Last Grouping Update2019-10-04 20:02:01PM
Last Indexed2019-11-13 04:54:46AM

Solr Details

accelerated_reader_point_value0
accelerated_reader_reading_level0
auth_author2Marlo, Coleen.
authorSharp, Kathleen.
author2-roleMarlo, Coleen.
hoopla digital.
author_displaySharp, Kathleen
available_at_lovelandLoveland Public Library
detailed_location_lovelandLoveland Adult Nonfiction
Online Hoopla Collection
display_description"Blood Feud is the electrifying true tale of Big Pharma's power, regulatory weakness, and the terrifying vulnerability of millions of innocent patients. THE PLAYERS The Drug: Procrit An anti-anemia drug, this miraculous blood booster was one of the first biotech blockbusters. Developed by Amgen and licensed to a Johnson & Johnson company, the drug was sold by the two companies under the brand names Procrit, Epogen, and Arenesp. The Underdog: Mark Duxbury, Drug Salesman Duxbury was the gung-ho salesman for the new biotech division of J&J, an irrepressible character full of jokes. In the early 1990s, he set out to spread the benefits of Procrit, and became a true believer and top seller. But he and his peers were told to steal business from J&J's partner, Amgen. Then came the marketing studies, the off-invoice rebates, doctor payments, and off-label claims. Duxbury tried to stop some of these ruthless programs, but was fired on trumped-up charges. He tried anything to warn the public: testifying in a secret arbitration, joining a class action effort, and filing a whistleblower suit. But he was thwarted at nearly every turn-until the surprising end. The Best Friend: Dean McClellan, Drug Legend Dean McClellan was Duxbury's friendly rival. He tried to beat his buddy's record and wound up selling $170 million worth of the drug, becoming a legend. When Duxbury got fired, McClellan tried to distance himself. But as news of Procrit's deadly power started to surface, McClellan agreed to hand over thousands of damning documents and help his friend blow the whistle on J&J. The Crusader: Jan Schlichtmann, Esq. Remember Jan Schlichtmann, protagonist of the best-selling book and Oscar nominated movie, A Civil Action? When he learned of Duxbury's mission, he felt the old fire rising in his belly and signed on. Now, he's gambling on yet another long shot, trying to fight on behalf of not just millions of cancer patients, but for every American who overpays for. health-care"--Provided by publisher.
format_category_lovelandAudio Books
Books
eBook
format_lovelandBook
eAudiobook
ida9088616-1cea-8082-ea59-ccfab8c92029
isbn9780525952404
9781452623764
item_details
Bib IdItem IdShelf LocCall NumFormatFormat CategoryNum CopiesIs Order ItemIs eContenteContent SourceeContent FileeContent URLsubformatDetailed StatusLast CheckinLocationSub-location
hoopla:MWT11186131Online Hoopla CollectionOnline HooplaeAudiobookAudio Books1falsetrueHooplahttps://www.hoopladigital.com/title/11186131?utm_source=MARCAvailable Online
ils:.b19098133.i40936739Loveland Adult Nonfiction338.476153 Sharp, K.1falsefalseOn ShelfMar 28, 2019lvnfa
itype_lovelandhardcover book
last_indexed2019-11-13T11:54:46.118Z
lexile_score-1
literary_formNon Fiction
literary_form_fullNon Fiction
local_callnumber_loveland338.476153 Sharp, K.
owning_library_lovelandLoveland Public Library
owning_location_lovelandLoveland Public Library
primary_isbn9780525952404
publishDate2011
record_details
Bib IdFormatFormat CategoryEditionLanguagePublisherPublication DatePhysical Description
hoopla:MWT11186131eAudiobookAudio BooksUnabridged.EnglishTantor Audio, 2011.1 online resource (1 audio file (840 min.)) : digital.
ils:.b19098133BookBooksEnglishDutton/Penguin Group, c2011.p. ; cm.
recordtypegrouped_work
scoping_details_loveland
Bib IdItem IdGrouped StatusStatusLocally OwnedAvailableHoldableBookableIn Library Use OnlyLibrary OwnedHoldable PTypesBookable PTypesLocal Url
hoopla:MWT11186131Available OnlineAvailable Onlinefalsetruefalsefalsefalsefalse
ils:.b19098133.i40936739On ShelfOn Shelffalsetruetruefalsefalsetrue128, 1, 129, 130, 2, 3, 131, 4, 133, 5, 6, 7, 135, 8, 136, 9, 10, 11, 12, 13, 17, 18, 19, 20, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 80, 81, 82, 84, 85, 86, 92, 93, 95, 96, 97, 98, 99, 100, 105, 106, 108, 109, 110, 115, 117, 118, 119, 125, 126, 127
subject_facetAmgen Inc
Anemia -- Drug therapy -- United States
Duxbury, Mark
Epoetin Alfa -- Adverse effects -- United States
Epoetin Alfa -- Economics -- United States
Johnson and Johnson, inc
Marketing of Health Services -- Economics -- United States
McClellan, Dean
Pharmaceutical industry -- Corrupt practices -- United States
Pharmaceutical industry -- Economics -- United States
Schlichtmann, Jan
Whistle blowing -- United States -- Case studies
Whistleblowing -- United States
title_displayBlood feud : the man who blew the whistle on one of the deadliest prescription drugs ever
title_fullBlood feud : the man who blew the whistle on one of the deadliest prescription drugs ever / Kathleen Sharp
Blood feud : the man who blew the whistle on one of the deadliest prescription drugs ever [electronic resource] / Kathleen Sharp
title_shortBlood feud
title_subthe man who blew the whistle on one of the deadliest prescription drugs ever
topic_facetAdverse effects
Anemia
Corrupt practices
Drug therapy
Duxbury, Mark
Economics
Epoetin Alfa
Marketing of Health Services
McClellan, Dean
Pharmaceutical industry
Schlichtmann, Jan
Whistle blowing
Whistleblowing